ReviewInternational journal of pharmaceutics2025
Albumin as a natural and moldable biomaterial for biomimetic drug delivery applications.
Review in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The lactate-to-albumin ratio as a potential biomarker for acute kidney injury risk in critically ill patients with heart failure: a retrospective study with real-world external validation.Frontiers in nutrition · 2026Article
- The lactate-to-albumin ratio as a potential biomarker for short-term mortality risk in critically ill patients with urosepsis: a retrospective study with dual-cohort validation.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Natural materials such as polysaccharides, lipids, and proteins have been widely explored for their potential as nanomaterials in advanced drug delivery systems (ADDS), aiming to develop personalized biomimetic delivery platforms. Among these, albumin, the most abundant plasma protein, has garnered significant attention for its use in nanoparticle-based-drug delivery systems. This review focuses on the evolution of albumin from a key physiological biomolecule to a sustainable, green biomaterial with therapeutic and bioengineering applications. A conceptual gap still exists in understanding the dual role of albumin as a physiological matrix and as a therapeutic agent for conditions like hypovolemia, while also serving as a bulk material for ADDS development. Albumin's unique biochemical properties contribute to its role in modulating age-related diseases and maintaining physiological homeostasis. Known for its function as a physiological buffer, albumin facilitates the transport of biomolecules, drugs, and metabolites across various compartments of the human body. Clinically, albumin solutions (ranging from 5% to 25% w/v) are used in intravenous infusions to treat critically ill patients. However, albumin's structural conformation is highly sensitive to external factors such as small molecules, salts, pH variations, and temperature fluctuations, leading to aggregation and conformational changes. This negatively charged globular protein, composed of 585 amino acids and rich in cysteine (Cys), is well-suited for ionic crosslinking and composite-based pharmaceutical strategies aimed at developing novel drug delivery systems. This review bridges the existing knowledge gap by examining albumin's biochemical, clinical, and pharmaceutical characteristics, particularly its moldable chemistries for the synthesis of nanoparticles, microbubbles, hydrogels, and 3D-printable structures. Furthermore, we discuss the pharmacopeial standards and FDA regulations governing the use of albumin in clinical versus research applications. Collectively, this review highlights recent trends in research, clinical applications, and the potential of albumin as a pharmaceutical excipient for developing personalized site-directed dosage formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.